Heyuan Biotech announced on October 30 that Pan Acuradong, the controlling shareholder, actual controller, and chairman of the company, proposed that the company use centralized bidding transactions to repurchase some of the company's issued RMB common shares through the Shanghai Stock Exchange trading system to protect the company's value and shareholders' rights. The total repurchase capital is not less than 25 million yuan, not more than 50 million yuan. The repurchase price is not higher than 150% of the average share transaction price in the 30 trading days before the board of directors of the company reviewed and approved the share repurchase plan. The details are subject to the share repurchase plan reviewed and approved by the board of directors.

Heyuan Biotech announced on October 30 that Pan Acuradong, the controlling shareholder, actual controller, and chairman of the company, proposed that the company use centralized bidding transactions to repurchase some of the company's issued RMB common shares through the Shanghai Stock Exchange trading system to protect the company's value and shareholders' rights. The total repurchase capital is not less than 25 million yuan, not more than 50 million yuan. The repurchase price is not higher than 150% of the average share transaction price in the 30 trading days before the board of directors of the company reviewed and approved the share repurchase plan. The details are subject to the share repurchase plan reviewed and approved by the board of directors.